Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures.
Recent Posts
New initiative to bridge the gap on antimicrobial innovation
By Stephen J. Ubl | July 9, 2020
Today, more than 20 leading biopharmaceutical companies are launching the AMR Action Fund, a ground-breaking partnership to invest nearly $1 billion to ensure a robust and diverse pipeline of new...
Read More
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
By Stephen J. Ubl | April 15, 2020
As biopharmaceutical companies continue to fight COVID-19 through research and development, three companies have created programs empowering employees with medical or laboratory expertise to...
Read More
COVID-19 Response: Supporting the frontline
By Stephen J. Ubl | March 30, 2020
Updated 7/13/2020 In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of...
Read More
Helping those affected by the coronavirus
By Stephen J. Ubl | February 20, 2020
Updated as of 6/11/2020 America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a disease caused by a novel strain of...
Read More
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
By Stephen J. Ubl | January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...
Read More
PhRMA CEO Statement Following Meeting With President Trump
By Stephen J. Ubl | January 31, 2017
This morning, we had a positive, productive meeting with President Trump, Vice President Pence and House Energy and Commerce Chairman Greg Walden, (R-Ore.). We talked about how we can work...
Read More
Improving FDA’s combination product review process could increase epinephrine auto-injector competition
By Stephen J. Ubl | August 30, 2016
Combination products that consist of a medicine and delivery device are important treatment options for patients and have the potential to improve public health. Innovator companies invest in...
Read More
PhRMA member companies invested $58.8 billion in R&D in 2015
By Stephen J. Ubl | May 12, 2016
For more than 30 years, the U.S. biopharmaceutical industry has been the world leader in the development of new medicines, driving innovation for patients. And PhRMA member companies continue to...
Read More
We are at a pivotal time in health care in America. Biomedical discovery and innovation have the potential to revolutionize the way we diagnose and treat patients. At the same time, rapidly...
Read More
PhRMA Statement on President’s FY2017 Budget
By Stephen J. Ubl | February 9, 2016
The biopharmaceutical industry is committed to advancing solutions for a competitive, value-based health care system that makes better use of today’s medicines and fosters the development of...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
